Navigation Links
AutoGenomics CYP 2C19 Test Used in Study to Personalize Clopidogrel (Plavix) Dosing in Patients
Date:1/22/2009

CARLSBAD, Calif., Jan. 22 /PRNewswire/ -- AutoGenomics, a leader in providing automated molecular testing solutions announced today that its CYP450 2C19 assay was used in a study to demonstrate the value of genetic variants in dosing of the antiplatelet agent, Plavix.

Plavix, commonly known as Clopidogrel, is an anti-platelet agent used in the treatment for coronary artery disease, peripheral vascular disease and cerebrovascular disease. To realize the antiplatelet effect, Clopidogrel requires biotransformation to an active metabolite by cytochrome P-450 enzymes.

"Personalizing Clopidogrel dosing using pharmacogenetics may be an effective method of rationalizing treatment. In a recent study we used the AutoGenomics 2C19 test to screen for polymorphisms associated with a reduced response to the drug" said Dr. Mark Webster, Director of Cardiac Catheterization at the Auckland City Hospital. His co-investigator Dr. Patrick Gladding said that "other studies have shown that patients treated with Clopidogrel with a reduced function CYP C219 genetic variant had lower levels of the active metabolite resulting in a reduced antiplatelet response to the drug and a three-fold risk of stent thrombosis."

"We are pleased that Dr. Webster and Dr. Gladding have taken a pioneering role in assessing the role of genetic variants in Clopidogrel dosing to ensure patient safety. The AutoGenomics platform enables the rapid testing of such CYP 450 tests including CYP 2C9, CYP 3A4 & CYP 3A5 that have been quoted in recent publications as factors that could be of interest in drug dosing" said Ramanath Vairavan, Senior Vice President at AutoGenomics. He further said "that recent studies published in the New England Journal of Medicine indicated that about 30% of the patients had at least one CYP 2C19 reduced function genetic variant". With such high incidence of these reduced functional alleles it is gratifying to note the active role that FDA is taking to re-label these drugs and help realize the promise of personalized medicine to ensure drug efficacy and patient safety".

About AutoGenomics

AutoGenomics Inc., a privately held company based in Carlsbad, CA, has developed the first automated, microarray based multiplexing diagnostic platform that can be used to assess disease signatures with novel genomic and proteomic markers in the area of genetic disorders, infectious disease, cancer and pharmacogenetics. With the discovery of genes and their link to various disease states the platform has the versatility to revolutionize the way patients are diagnosed, monitored and managed leading to the era of personalized medicine. www.autogenomics.com


'/>"/>
SOURCE AutoGenomics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. AutoGenomics Receives FDA Clearance for its INFINITI(TM) Warfarin Assay
2. AutoGenomics Receives a Key European Patent for HPV Detection
3. AutoGenomics INFINITI Analyzer Receives Artistic Design Award
4. AutoGenomics, Inc. Files Registration Statement for Initial Public Offering
5. Penn study finds pro-death proteins required to regulate healthy immune function
6. New study shows promise in reducing surgical risks associated with surgical bleeding
7. Study, meta-analysis examine factors associated with death from heatstroke
8. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
9. Study says COPD testing is not measuring up
10. Preclinical study suggests organ-transplant drug may aid in lupus fight
11. Ability to cope with stress can increase good cholesterol in older white men, study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... , ... October 13, 2017 ... ... of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ... on guideline updates for the primary prevention of cardiovascular diseases during the ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for professional ... action towards gender equality at their inaugural Summit in New York City in June. ... a social audience of over 3 million. To watch the Mobilize Women video, ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to the ... save lost souls in the Philippines. “The Journey: From the Mountains to the Mission ... of the Bible. She has taught all ages and currently teaches a class of ...
(Date:10/12/2017)... Wis. (PRWEB) , ... October 12, 2017 , ... ... standard products to meet the demand of today’s consumer and regulatory authorities worldwide. ... of probiotic experts and tested to meet the highest standard. , These ...
(Date:10/12/2017)... ... 12, 2017 , ... Dr. Parsa Mohebi, the Los Angeles ... to the newly revamped Cosmetic Town journal section, featuring articles written ... known as Follicular Unit Extraction (FUE). , Dr. Mohebi says “I ...
Breaking Medicine News(10 mins):
(Date:9/19/2017)... 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically ... announced three leadership team developments today:   ... ... Tom ... Veteran medical device executive Josh Stopek , PhD, who ...
(Date:9/18/2017)... , Pa. and KALAMAZOO, Mich. , ... Allentown, Penn. , and OptiMed Specialty Pharmacy of ... business partnership to offer a strategic hub service that ... Healthcare,s highly sought-after personal spirometer, Spiro PD 2.0, and ... A spirometer is a medical device used to ...
(Date:9/13/2017)... , Sept. 13, 2017   OrthoAtlanta has ... the Atlanta Football Host Committee (AFHC) for the 2018 College ... Jan. 8, 2018, at Mercedes-Benz Stadium in Atlanta, ... of the AFHC "I,m In" campaign, participating in many activities ... ...
Breaking Medicine Technology: